January 31, 2019
Eisai said on January 30 that it has filed its epilepsy drug Fycompa (perampanel) seeking Japanese regulatory approval for use as monotherapy for partial-onset seizures and for an additional indication of partial-onset seizures in children aged four years and older...read more